Blood Disorder Treatments at King Faisal Specialist Hospital in Saudi Arabia
5,100+ bone marrow transplants, 140+ paediatric stem cell transplants annually, treating sickle cell disease, thalassaemia, leukaemia, lymphoma, and myeloma.
Why Choose KFSH&RC for Haematology and Blood Disorder Treatments in Saudi Arabia
Only centre in the Arab world to manufacture CAR-T cell therapy in-house
- 92% 5-year survival rate for childhood leukaemia (ALL).
- Reports reviewed remotely before you commit to travel.
- Dedicated coordinator assigned from your first enquiry.
- Patients from 17 countries treated in 2024.
- Remote monitoring via AlTakhassusi App post-discharge.
- Accommodation assistance available near all 4 campuses.
Advanced Technology for Haematology and Blood Disorder Treatments at KFSH&RC
- In-House CAR-T Manufacturing
- High Resolution HLA Typing
- Next Generation Sequencing (NGS)
- Multi-Parameter Flow Cytometry
- Fluorescence In Situ Hybridisation (FISH)
- Haematopoietic Stem Cell Cryopreservation
- Bone Marrow Trephine Biopsy
- Molecular Minimal Residual Disease (MRD) Testing
Haematology and Blood Disorder Treatments at KFSH&RC for International Patients
Each case is assessed by a team of haematologists, transplant physicians, and molecular specialists who review your diagnosis before confirming a personalised treatment plan.
Bone Marrow Transplant
5,100+ transplants; EBMT, CIBMTR, NMDP, and COG accredited; rare simultaneous quadruple accreditation globally.
Inquire
Sickle cell treatment
Dedicated programme including bone marrow transplant as curative option; robotic splenectomy available for eligible patients.
Inquire
Thalassaemia Care
Bone marrow transplant as curative therapy for eligible patients; regular transfusion and chelation programmes.
Inquire
Leukaemia Treatment
ALL, AML, CLL, CML treated with chemotherapy, targeted agents, CAR-T, and bone marrow transplant pathways.
Inquire
Lymphoma Treatment
Hodgkin's and non-Hodgkin's lymphoma; disease-specific tumour board review; CAR-T available for relapsed/refractory cases.
Inquire
Aplastic Anaemia
Bone marrow transplant and immunosuppressive therapy; paediatric and adult programmes.
Inquire
Multiple Myeloma
High-dose chemotherapy, autologous stem cell transplant, and CAR-T available for relapsed/refractory cases.
Inquire
Stem Cell Transplant
Allogeneic and autologous stem cell transplant for leukaemia, lymphoma, myeloma, sickle cell, thalassaemia; EBMT, CIBMTR, NMDP, and COG accredited simultaneously.
Inquire
CAR-T Cell Therapy
Only Arab world centre manufacturing CAR-T in-house; 200+ patients treated since 2020; 50% faster manufacturing vs commercial products; covers B-cell lymphomas, ALL, and myeloma.
Inquire
Sickle Cell Disease
Stem cell transplant as a curative option; robotic splenectomy available; newborn screening programme; highest regional volume for this condition.
Inquire
Thalassaemia
Stem cell transplant for eligible patients; lifelong transfusion and chelation programmes; paediatric programme active since 1984.
Inquire
Lymphoma
Hodgkin's and non-Hodgkin's lymphoma; disease-specific multidisciplinary tumour board; CAR-T available for relapsed and refractory cases.
Inquire
Multiple Myeloma
High-dose chemotherapy, autologous stem cell transplant, and in-house CAR-T for relapsed and refractory myeloma.
Inquire
Care Journey for International Patients
Your cancer treatment journey made simple and stress-free in 5 easy steps
-
1
Online inquiry & medical files upload Share your medical reports for review. It takes less than a minute.
-
2
Doctor review & treatment plan Within 24hrs you will receive treatment options & a preliminary plan before travel.
-
3
Travel coordination We arrange your visa, flights, and accommodation.
-
4
Treatment phase Full care under a dedicated case manager.
-
5
Start your treatment Begin treatment with full support from our care team.
Frequently Asked Questions
Have a question? Our support team is here to guide you through each step of your treatment journey with personal care and attention.Can KFSH&RC review my blood results and bone marrow biopsy before I travel?
Yes. Submit your full blood panel, bone marrow biopsy, cytogenetics, and molecular studies for a remote assessment before you commit to travel.
You receive a written clinical evaluation confirming your case fit and the specialist team assigned.
Send reports via WhatsApp at +1 718 550 0880 or email [email protected].
Does KFSH&RC manufacture CAR-T cell therapy on site?
Yes. KFSH&RC is the only centre in the Arab world with an in-house CAR-T manufacturing facility.
T-cells are harvested, genetically modified, and reinfused on site without the 4-6 week international shipping delay of commercial products.
Since 2020, 200+ patients have received in-house CAR-T therapy with manufacturing time reduced by 50%.
The programme covers B-cell lymphomas, ALL, and multiple myeloma.
Does KFSH&RC treat children with blood disorders and leukaemia?
Yes. The paediatric programme runs through King Fahad National Centre for Children's Cancer on the Riyadh campus, accredited by the Children's Oncology Group.
It performs 140+ paediatric stem cell transplants annually with a 92% five-year survival rate for childhood ALL.
Conditions include leukaemia, lymphoma, sickle cell disease, thalassaemia, aplastic anaemia, and rare inherited bone marrow disorders.
How do I contact the international patient support team for haematology treatment at KFSH&RC?
Haematology consultations and treatment coordination at KFSH&RC are managed through the International Patient Care Centre.
- WhatsApp: +1 718 550 0880
- Telephone: +1 718 550 0880
- Email: [email protected]
Available 24/7 for online consultations, remote report reviews, and full coordination with your assigned haematologist.
How long do I need to stay in Saudi Arabia for haematology treatment?
Stay duration depends on treatment:
- Allogeneic stem cell transplant: 6-10 weeks inpatient
- Autologous stem cell transplant: 4-6 weeks
- CAR-T cell therapy: 4-8 weeks with CRS monitoring
- Leukaemia induction chemotherapy: 4-6 weeks first cycle
- Targeted therapy or biologics: often outpatient
- 1-2 weeks for assessment Your coordinator provides a written itinerary before you book flights.
Is KFSH&RC internationally accredited for stem cell transplantation?
Yes. KFSH&RC holds simultaneous accreditation from EBMT, CIBMTR, NMDP, and the Children's Oncology Group.
This combination of four accreditations is held by fewer than a handful of centres globally, confirming KFSH&RC meets the highest standards for transplant outcomes, data reporting, and protocol compliance.
Which blood disorders bring GCC patients to KFSH&RC most often?
The four most common presentations are sickle cell disease requiring stem cell transplant as a curative option, thalassaemia requiring transplant evaluation, relapsed or refractory leukaemia or lymphoma requiring CAR-T therapy, and aplastic anaemia or MDS requiring allogeneic transplant.
Qatar, Bahrain, Oman, and Kuwait lack an in-house CAR-T programme. KFSH&RC is the only Arab world centre where this is available without travelling to Europe or the United States.
